Skip to main content

Table 3 Characteristics associated with MDR-TB treatment outcomes

From: Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania

Clinical/microbiological characteristic

Treatment success

N = 24

Treatment failure

N = 6

p-value

Mean age years ±SD

34 ± 10

28 ± 9

P = 0.20

Gender, Female (%N)

6 (25)

1 (16.7)

P = 0.57

HIV infected (%N)

5 (20.8)

1 (20)

P = 0.66

Smoking (%N)

6 (25)

0

P = 0.33

Prior treatment

21 (87.5)

4 (66.7)

P = 0.25

Cavity on chest x-ray

6 (25)

2 (33.3)

P = 0.65

PZA resistant (%N) by MGIT PZA

10 (41.6)

5 (83)

P = 0.08

  1. SD standard deviation, HIV human immunodeficiency virus, PZA pyrazinamide